From Wikipedia, the free encyclopedia
Chemical compound
Fotagliptin (SAL067 ) is a
DPP-4 inhibitor under development for the treatment of
type 2 diabetes . Like other DPP-4 inhibitors, it works by increasing endogenously produced
GLP-1 and
GIP .
[1]
[2]
[3] In a phase 3 trial it showed similar results as
alogliptin .
[4]
References
^ Wu, Min; Li, Qian‐Qian; Zhang, Hong; Zhu, Xiao‐Xue; Li, Xiao‐Jiao; Li, Ying; Sun, Hai‐Gang; Ding, Yan‐Hua (June 2021).
"Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus" . Clinical Pharmacology in Drug Development . 10 (6): 660–668.
doi :
10.1002/cpdd.895 .
ISSN
2160-763X .
PMID
33440080 .
S2CID
231606176 .
^ Fang, Lan; Gao, Zhenguo; Wu, Songgu; Jia, Shengzhe; Wang, Jingkang; Rohani, Sohrab; Gong, Junbo (1 August 2021).
"Ultrasound-assisted solution crystallization of fotagliptin benzoate: Process intensification and crystal product optimization" . Ultrasonics Sonochemistry . 76 : 105634.
doi :
10.1016/j.ultsonch.2021.105634 .
ISSN
1350-4177 .
PMC
8261672 .
PMID
34218067 .
^ Ding, Yanhua; Zhang, Hong; Li, Cuiyun; Zheng, WenBo; Wang, Meng; Li, Ying; Sun, HaiGang; Wu, Min (3 June 2021). "Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology . 17 (6): 725–731.
doi :
10.1080/17425255.2021.1915283 .
PMID
33899649 .
S2CID
233400233 .
^ Xu, Mingtong; Sun, Kan; Xu, Wenjie; Wang, Chuan; Yan, Dewen; Li, Shu; Cong, Li; Pi, Yinzhen; Song, Weihong; Sun, Qingyuan; Xiao, Rijun; Peng, Weixia; Wang, Jianping; Peng, Hui; Zhang, Yawei; Duan, Peng; Zhang, Meiying; Liu, Jianying; Huang, Qingmei; Li, Xuefeng; Bao, Yan; Zeng, Tianshu; Wang, Kun; Qin, Li; Wu, Chaoming; Deng, Chunying; Huang, Chenghu; Yan, Shuang; Zhang, Wei; Li, Meizi; Sun, Li; Wang, Yanjun; Li, HongMei; Wang, Guang; Pang, Shuguang; Zheng, Xianling; Wang, Haifang; Wang, Fujun; Su, Xiuhai; Ma, Yujin; Zhang, Wei; Li, Ziling; Xie, Zuoling; Xu, Ning; Ni, Lin; Zhang, Li; Deng, Xiangqun; Pan, Tianrong; Dong, Qijuan; Wu, Xiaohong; Shen, Xingping; Zhang, Xin; Zou, Qijing; Jiang, Chengxia; Xi, Jue; Ma, Jianhua; Sun, Jingchao; Yan, Li (2023).
"Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial" . BMC Medicine . 21 (1): 388.
doi :
10.1186/s12916-023-03089-x .
ISSN
1741-7015 .
PMC
10563289 .
PMID
37814306 .